Page last updated: 2024-08-16

technetium tc 99m sestamibi and biricodar

technetium tc 99m sestamibi has been researched along with biricodar in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Atkins, F; Bhatnagar, A; Chaturvedi, PR; Harding, MW; Hawkins, MJ; Hewett, J; Peck, RA; Wang, YM; Ziessman, H	1
Bates, SF; Chen, C; Figg, WD; Fojo, T; Kang, M; Robey, R	1

Reviews

1 review(s) available for technetium tc 99m sestamibi and biricodar

Article	Year
Reversal of multidrug resistance: lessons from clinical oncology. Novartis Foundation symposium, 2002, Volume: 243 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzazepines; Clinical Trials as Topic; Cyclosporins; Dibenzocycloheptenes; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorescent Dyes; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Mice; Mice, Knockout; Neoplasm Proteins; Neoplasms; Piperidines; Pyridines; Quinolines; Radionuclide Imaging; Radiopharmaceuticals; Rhodamines; Technetium Tc 99m Sestamibi; Tissue Distribution; Tumor Cells, Cultured	2002

Article

Year

Reversal of multidrug resistance: lessons from clinical oncology.

Novartis Foundation symposium, 2002, Volume: 243

Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzazepines; Clinical Trials as Topic; Cyclosporins; Dibenzocycloheptenes; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorescent Dyes; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Mice; Mice, Knockout; Neoplasm Proteins; Neoplasms; Piperidines; Pyridines; Quinolines; Radionuclide Imaging; Radiopharmaceuticals; Rhodamines; Technetium Tc 99m Sestamibi; Tissue Distribution; Tumor Cells, Cultured

2002

Trials

1 trial(s) available for technetium tc 99m sestamibi and biricodar

Article	Year
Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jun-15, Volume: 19, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Female; Half-Life; Humans; Infusions, Intravenous; Liver; Male; Maximum Tolerated Dose; Middle Aged; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Neoplasms; Piperidines; Pyridines; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Tissue Distribution	2001

Article

Year

Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jun-15, Volume: 19, Issue:12

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Female; Half-Life; Humans; Infusions, Intravenous; Liver; Male; Maximum Tolerated Dose; Middle Aged; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Neoplasms; Piperidines; Pyridines; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Tissue Distribution

2001